ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Open Access
Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)Useful Links
Recommended Journals
Related Subjects
In Association with
Virtual screening for the discovery of new anticoagulants
5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit
September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA
| Horacio P?rez-S?nchez |
| Accepted Abstracts: J Bioequiv Availab |
| DOI: 10.4172/0975-0851.S1.019 |
| Abstract |
| T he discovery of novel anticoagulants without side effects is one of the main problems of haemostasis. Ever since the discovery of the anticoagulant properties of hirudin from the leech saliva, the increasing relevance of thromboembolic diseases has encouraged a continuous search for new compounds with anticoagulant activity, which have led to the development of the new commercially available anticoagulants. One of the targets for prophylaxis and treatment of thromboembolic diseases is the plasma anticoagulant antithrombin. This protein circulates in blood in a metastable conformation, in which the reactive centre loop is partially inserted and is only activated by heparin and heparin sulfate glycosaminoglycans on the injured subendothelium. Accordingly sulfated polysaccharide heparin chains with different size, from unfractionated to the essential pentasaccharide, have been used with more or less success in anticoagulant therapy and thromboprophilaxis. In the last decades new molecules able to bind antithrombin have been identified. The strategies used in this search have been based mainly on the synthesis or chemical modification of existing drugs, or in the application of natural compounds with similar properties to those currently used. Examples for such compounds are lignins and flavonoids, highly sulfated small organic ligands that seem to have similar properties to heparins. Therefore, the discovery of novel or improved drugs for given diseases or special groups of patients, is a very slow and expensive process. Nevertheless, recent results obtained by the speaker demonstrate the discovery using Virtual Screening (VS) of a novel molecular scaffold, different to the previous ones based on heparin. Using this alternate approach, a large database of millions of chemical compounds is screened in-silico and affinity-ranking is used to identify some at least weakly-binding molecules for further refinement. Aided by ever-increasing computational power, VS is an appealing and cost-effective approach to tap into the wealth of available structural information. Consequently, novel and enhanced VS methodologies, conveniently exploited in innovative drug discovery strategies can lead to significant and quantifiable developments. |
 PDF |  HTML |
Relevant Topics
- Advances in Bioavailability
- Advances in pharmaceutical analytical methods
- Air analysis
- Anthropology Biomedicine
- Antigen â Antibody Reaction
- Anvisa Bioequivalence
- Anvisa regulatory guidelines
- Applied Biomedicine
- BA/BE Studies
- Bioanalysis Methods
- Bioanalytical Chemistry
- Bioanalytical Method Validation
- Bioequivalence Anticancers
- Bioequivalence Antidiabetics
- Bioequivalence Antidiuretics
- Bioequivalence Antipsychotics
- Bioequivalence Cardiovascular Products
- Bioequivalence Study Design
- Bioequivalence Study Protocols
- Biomedicine and Pharmacotherapy
- Biopharmaceutics
- Biosimilars
- British regulatory guidelines
- Cell genetics
- Chemical analysis
- Chromatographic Techniques
- Clinical Cancer Trials
- Clinical Drug Trial
- Competitive analysis of drugs
- Computational Biomedicine
- Drug Delivery using Nanotechnology
- Drug Designing
- Drug analysis
- Drug devices
- European Bioequivalence
- Europian regulatory guidelines
- Experimental Drug Trial
- FDA Bioequivalence
- Fragment Based Drug Design
- Heat Shock Proteins
- In Silico Methods
- In vitro Bioequivalence
- Japan regulatory guidelines
- Marine Biomedicine
- Mass Spectroscopy
- Medical Biology
- Medical devices regulations
- Molecular Biomedicine
- Molecular Epidemiology
- Molecular Modeling
- NMR Applications in Biomedicine
- Nano Medicine
- Nanomedicals
- Negative Results in Biomedicine
- Paid Clinical Trials
- Peptidomimetic
- Pharmaceutical analysis
- Pharmaceutical analytical market
- Pharmaceutical care
- Pharmaceutical companies and regulatory guidelines
- Pharmaceutical ethics
- Pharmaceutical formulation
- Pharmaceutical technology
- Pharmaceutics
- Product analysis and marketing
- Protease Substrate/Inhibitor
- Quality assurance in pharmaceutical analysis
- Quality assurance in regulatory affairs
- Receptor Agonist/ Antagonist
- Regulatory Requirements in Bioequivalence
- Regulatory affairs
- Regulatory affairs for clinical trails
- Regulatory compliance
- Regulatory consulting and market analysis
- Regulatory requirements of pharmaceutical products
- Regulatory services and market analysis
- Spectrometry
- Sports Biomedicine
- Structure Based Drug Design
- Systems Biomedicine
- US FDA guidelines
- Validation
- screening and Drug Design
